CMAJ| AUGUST 10, 2020| VOLUME 192| ISSUE 32 E929 access to interprovincially shared
routinely collected clinical data (more rapid than the months to a year it currently takes to …

A common perception that research is a costly diversion from clinical care exacerbates this
problem and makes it difficult to persuade sites to participate in clinical studies. Furthermore …

We believe that Canada needs to ensure the necessary infrastructure is in place to support
enrolment of patients with COVID-19 in treatment trials, making it simple for all clinicians to …

We are witnessing an increasing demand for rapid, rigorous, and generalizable evidence to
inform health care systems' learning and address inefficiencies in the current clinical trials …

The emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), sparking a global pandemic, 1 has driven an imperative to quickly design and conduct …

This perspective explores the landscape of COVID-19 trials recruiting in Australia using trial
registry data. We identified 56 trials addressing treatment and prevention of COVID-19, and …

Background The failure of randomised controlled trials to adequately reflect areas of highest
health need have been repeatedly highlighted. This has implications for the validity and …

Background Rapid identification of effective treatments for use in the community during a
pandemic is vital for the well-being of individuals and the sustainability of healthcare …

Objective Clinical trial data sharing has the potential to accelerate scientific progress,
answer new lines of scientific inquiry, support reproducibility and prevent redundancy. Vivli …

COVID-19 has had negative repercussions on the entire global population. Despite there
being a common goal that should have unified resources and efforts, there have been an …